Suppr超能文献

供体CD4+CD25+ T细胞在MHC不匹配的造血细胞移植后促进植入和耐受。

Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation.

作者信息

Hanash Alan M, Levy Robert B

机构信息

University of Miami Miller School of Medicine, Department of Microbiology and Immunology, PO Box 016960, Miami, FL 33101, USA.

出版信息

Blood. 2005 Feb 15;105(4):1828-36. doi: 10.1182/blood-2004-08-3213. Epub 2004 Oct 19.

Abstract

Allogeneic bone marrow transplantation (BMT) is a potentially curative treatment for both inherited and acquired diseases of the hematopoietic compartment; however, its wider use is limited by the frequent and severe outcome of graft-versus-host disease (GVHD). Unfortunately, efforts to reduce GVHD by removing donor T cells have resulted in poor engraftment and elevated disease recurrence. Alternative cell populations capable of supporting allogeneic hematopoietic stem/progenitor cell engraftment without inducing GVHD could increase numbers of potential recipients while broadening the pool of acceptable donors. Although unfractionated CD4(+) T cells have not been shown to be an efficient facilitating population, CD4(+)CD25(+) regulatory cells (T-reg's) were examined for their capacity to support allogeneic hematopoietic engraftment. In a murine fully major histocompatibility complex (MHC)-mismatched BMT model, cotransplantation of donor B6 T-reg's into sublethally conditioned BALB/c recipients supported significantly greater lineage-committed and multipotential donor progenitors in recipient spleens 1 week after transplantation and significantly increased long-term multilineage donor chimerism. Donor engraftment occurred without GVHD-related weight loss or lethality and was associated with tolerance to donor and host antigens by in vitro and in vivo analyses. Donor CD4(+)CD25(+) T cells may therefore represent a potential alternative to unfractionated T cells for promotion of allogeneic engraftment in clinical hematopoietic cell transplantation.

摘要

异基因骨髓移植(BMT)是一种对造血系统遗传性和获得性疾病都具有潜在治愈作用的治疗方法;然而,移植物抗宿主病(GVHD)频繁且严重的后果限制了其更广泛的应用。不幸的是,通过去除供体T细胞来减少GVHD的努力导致植入不佳和疾病复发率升高。能够支持异基因造血干细胞/祖细胞植入而不诱导GVHD的替代细胞群体,可能会增加潜在受者的数量,同时扩大可接受供体的范围。虽然未分离的CD4(+) T细胞尚未被证明是一种有效的促进群体,但已对CD4(+)CD25(+)调节性细胞(T-reg细胞)支持异基因造血植入的能力进行了研究。在小鼠完全主要组织相容性复合体(MHC)不匹配的BMT模型中,将供体B6 T-reg细胞共移植到亚致死剂量照射的BALB/c受体中,在移植后1周,受体脾脏中支持了显著更多的定向谱系和多能供体祖细胞,并显著增加了长期多谱系供体嵌合现象。供体植入发生时没有与GVHD相关的体重减轻或致死情况,并且通过体外和体内分析显示与对供体和宿主抗原的耐受性相关。因此,在临床造血细胞移植中,供体CD4(+)CD25(+) T细胞可能是未分离T细胞促进异基因植入的潜在替代物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验